ID   Tera-CP
AC   CVCL_A5AF
DR   Wikidata; Q107117025
RX   PubMed=8242627;
RX   PubMed=12093475;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Derived from site: Metastatic; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3752; Embryonal carcinoma
DI   ORDO; Orphanet_180226; Embryonal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3407 ! NT2-D1
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=8242627;
RA   Timmer-Bosscha H., Timmer A., Meijer C., de Vries E.G.E., de Jong B.,
RA   Oosterhuis J.W., Mulder N.H.;
RT   "cis-diamminedichloroplatinum(ii) resistance in vitro and in vivo in
RT   human embryonal carcinoma cells.";
RL   Cancer Res. 53:5707-5713(1993).
//
RX   PubMed=12093475; DOI=10.1016/S0006-2952(02)00983-8;
RA   Fokkema E., Groen H.J.M., Helder M.N., de Vries E.G.E., Meijer C.;
RT   "JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to
RT   platinum-DNA adduct formation, glutathione levels and p53 status in
RT   human tumour cell lines with different sensitivities to cisplatin.";
RL   Biochem. Pharmacol. 63:1989-1996(2002).
//